- Home
- TCRX vs ELDN Comparison
TCRX vs ELDN Comparison
Compare TCRX & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- ELDN
- Stock Information
- Founded
- TCRX 2018
- ELDN 2004
- Country
- TCRX United States
- ELDN United States
- Employees
- TCRX N/A
- ELDN N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- TCRX Health Care
- ELDN Health Care
- Exchange
- TCRX Nasdaq
- ELDN Nasdaq
- Market Cap
- TCRX 140.7M
- ELDN 164.1M
- IPO Year
- TCRX 2021
- ELDN N/A
- Fundamental
- Price
- TCRX $1.89
- ELDN $4.29
- Analyst Decision
- TCRX Strong Buy
- ELDN Strong Buy
- Analyst Count
- TCRX 5
- ELDN 2
- Target Price
- TCRX $9.40
- ELDN $12.50
- AVG Volume (30 Days)
- TCRX 656.4K
- ELDN 1.7M
- Earning Date
- TCRX 11-07-2025
- ELDN 11-12-2025
- Dividend Yield
- TCRX N/A
- ELDN N/A
- EPS Growth
- TCRX N/A
- ELDN N/A
- EPS
- TCRX N/A
- ELDN 0.21
- Revenue
- TCRX $6,961,000.00
- ELDN N/A
- Revenue This Year
- TCRX $255.18
- ELDN N/A
- Revenue Next Year
- TCRX N/A
- ELDN N/A
- P/E Ratio
- TCRX N/A
- ELDN $20.51
- Revenue Growth
- TCRX N/A
- ELDN N/A
- 52 Week Low
- TCRX $1.02
- ELDN $2.32
- 52 Week High
- TCRX $6.23
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- TCRX 39.56
- ELDN 76.90
- Support Level
- TCRX $1.74
- ELDN $3.18
- Resistance Level
- TCRX $2.43
- ELDN $4.52
- Average True Range (ATR)
- TCRX 0.18
- ELDN 0.35
- MACD
- TCRX -0.07
- ELDN 0.12
- Stochastic Oscillator
- TCRX 14.46
- ELDN 86.60
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.